Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Baobao Cai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2837-7427; OpenAlex author ID A5063476562. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2013: 3 papers · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 19

  1. Comparison of Radical Antegrade Modular Pancreatosplenectomy Versus Standard Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Mat… Co-author DOI 10.1002/wjs.12630↗
  2. Cancer-testis gene STK31 is regulated by methylation and promotes the development of pancreatic cancer. First author DOI 10.1002/cam4.5472↗
  3. Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters. First author DOI 10.1016/j.sopen.2023.03.001↗
  4. Incidence of Pancreatic Cancer by Age and Sex in the US From 2000 to 2018. Co-author DOI 10.1001/jama.2022.2312↗
  5. A histopathological study of artery wall involvement in pancreatic cancer surgery. Co-author DOI 10.1007/s00423-022-02689-0↗
  6. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  7. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  8. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST… Co-author DOI 10.1016/j.pan.2021.05.300↗
  9. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Co-author DOI 10.1155/2021/6530298↗
  10. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  11. Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. Co-author DOI 10.1007/s00268-019-05325-z↗
  12. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer. Co-author DOI 10.1111/jcmm.15718↗
  13. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Co-author DOI 10.1016/j.prp.2019.152666↗
  14. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.1177/1533033819887962↗
  15. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regul… Co-author DOI 10.1186/s12943-018-0761-9↗
  16. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2017.03.024↗
  17. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. First author DOI 10.1016/j.canlet.2012.11.005↗
  18. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer. Co-author DOI 10.3760/cma.j.issn.0366-6999.20130748↗
  19. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Co-author DOI 10.3892/or.2013.2297↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zipeng Lu · 15 shared papers, 2013–2025 · strength 1.89
  2. Yi Miao · 12 shared papers, 2013–2023 · strength 1.65
  3. Kuirong Jiang · 14 shared papers, 2013–2022 · strength 1.32
  4. Pengfei Wu · 8 shared papers, 2013–2022 · strength 0.75
  5. Yi Miao · 7 shared papers, 2013–2025 · strength 0.69
  6. Xumin Huang · 4 shared papers, 2021–2025 · strength 0.60
  7. Guodong Shi · 6 shared papers, 2018–2021 · strength 0.56
  8. Qun Chen · 4 shared papers, 2020–2022 · strength 0.46
  9. Junli Wu · 4 shared papers, 2013–2025 · strength 0.46
  10. Kuirong Jiang · 3 shared papers, 2013–2025 · strength 0.45
  11. Kai Zhang · 2 shared papers, 2021–2022 · strength 0.39
  12. Jishu Wei · 4 shared papers, 2013–2025 · strength 0.39
  13. Meng Cao · 4 shared papers, 2019–2021 · strength 0.39
  14. Pengbo Zhang · 4 shared papers, 2019–2021 · strength 0.39
  15. John P. Neoptolemos · 3 shared papers, 2020–2022 · strength 0.35
  16. Tianfang Xia · 4 shared papers, 2018–2020 · strength 0.33
  17. Guangfu Wang · 2 shared papers, 2021–2023 · strength 0.33
  18. Hao Yuan · 3 shared papers, 2018–2022 · strength 0.32
  19. Kai Zhang · 2 shared papers, 2020–2023 · strength 0.29
  20. Pengfei Wu · 3 shared papers, 2019–2021 · strength 0.29
  21. Xinquan Wu · 3 shared papers, 2019–2020 · strength 0.26
  22. Lingdi Yin · 2 shared papers, 2021–2022 · strength 0.25
  23. Markus Wolfgang Büchler · 2 shared papers, 2021–2022 · strength 0.25
  24. Taoyue Yang · 2 shared papers, 2021–2022 · strength 0.25
  25. Lingdong Meng · 2 shared papers, 2021–2022 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.